The MoBot Report

October 21, 2024

DENVER, Colo., Oct 21, 2024 (247marketnews.com)- MoBot’s recent alerts included Bright Minds (NASDAQ: DRUG), BioVie (NASDAQ: BIVI), Siyata Mobile (NASDAQ: SYTA), T-Mobile’s (NASDAQ: TMUS), Genprex (NASDAQ: GNPX), and GRI Bio (NASDAQ: GRI).

MoBot posted Bright Minds (NASDAQ: DRUG) last week, before it ran to a new 52-week high of $79.02.

Bright Minds Biosciences (NASDAQ: DRUG) stated that it is again collaborating with Firefly Neuroscience (NASDAQ: AIFF) to thoroughly evaluate the electroencephalogram (EEG) data in Bright Minds’ BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

Bright Minds and Firefly previously collaborated to analyze the data from Bright Minds’ first-in-human Phase 1 study of BMB-101 using Firefly’s BNA technology platform.

Bright Minds Hit $62.99, today and closing in on 8 million shares traded.

“We believe BMB-101 has the potential to be a best-in-class 5-HT2C agonist. This compound is not only poised to make a significant impact in both the DEE and Absence Epilepsy communities, but also has broad applicability across the 30% of all epilepsy patients who experience drug resistance.”

BioVie (NASDAQ: BIVI) started squuezing a few days after it announced that it received a Notice of Allowance from the Japan Patent Office for patent application no. 2021-569344 entitled “Formulations of Terlipressin. MoBot alerted the move at $1.27, before it raced to $2.88. BioVie continues to run, hitting $7.50, on trading volume of more than 130 million shares.

MoBot spotted Siyata Mobile (NASDAQ: SYTA) on Oct 1 at $1.012 and again, this morning, at $1.334, following its announcement that its SD7 Ultra series 5G mission-critical push-to-talk (MCPTT) cellular radio handsets will be available on T-Mobile’s (NASDAQ: TMUS) 5G network.

Siyata Mobile’s SD7 Ultra series cellular radio handsets are designed to be used by public safety officials with applications that enhance operational awareness and improve response times in critical situations. Siyata hit $2.92, on over 115 million shares.

Genprex’s (NASDAQ: GNPX) moves on Friday caught MoBot’s attention, at $0.423, a few days after it reported, last week, that it completed the 0.09 mg/kg dose group of the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC). Genprex traded as high as $2.04 and should soon pass 250 million shares traded.

GRI Bio (NASDAQ: GRI) started running on Wednesday, following that news that it presented of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) being held October 12-16, 2024 in Athens, Greece. MoBot reported the move on Wednesday at $0.415 and it hit a high of $1.79, on over 103 million shares.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

24/7 Market News disclosure

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (DRUG, BIVI, SYTA, TMUS), GNPX, GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.